Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy

doi:10.3748/wjg.v32.i22.117417

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 22

This Article

(29)

(26)

(0)

(34)

(504)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jun 14, 2026; 32(22): 117417
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.117417

Full Size Figure Download Figure

Figure 5 Comparative analysis of adjuvant chemotherapy benefit in human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative patients before and after propensity score matching. A: Kaplan-Meier survival curve for overall survival (OS) in human epidermal growth factor receptor 2 (HER2)-negative patients before propensity score matching (PSM), showing a significant benefit from adjuvant chemotherapy; B: Kaplan-Meier survival curve for OS in HER2-positive patients before PSM, showing no significant difference between chemotherapy and non-chemotherapy groups; C: Kaplan-Meier survival curve for OS in HER2-negative patients after PSM, confirming the continued survival benefit of adjuvant chemotherapy; D: Kaplan-Meier survival curve for OS in HER2-positive patients after PSM, validating no significant benefit from conventional chemotherapy.

Citation: Han RY, Wei YK, Liu WN, Wang YM, Song TQ, Tian XD, Xia YR, Chen L, Gong WC. Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy. World J Gastroenterol 2026; 32(22): 117417
URL: https://www.wjgnet.com/1007-9327/full/v32/i22/117417.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i22.117417

Han RY, Wei YK, Liu WN, Wang YM, Song TQ, Tian XD, Xia YR, Chen L, Gong WC. Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy. World J Gastroenterol 2026; 32(22): 117417 [DOI: 10.3748/wjg.v32.i22.117417]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.